论文部分内容阅读
目的:分析对腹泻患儿联合给药喜炎平和思密达的临床效果和安全性。方法:将我院2014年1月-2014年12月之间收治的116例腹泻患儿作为观察对象,随机将其分为观察组和对照组各58例。对照组患儿的给药喜炎平治疗,观察组在对照组基础上给药思密达。分析对比两组患儿的治疗效果以及不良反应的发生率。结果:对照组患者的治疗总有效率为55(94.83%),观察组患儿的治疗有效率为45(77.59%),结果差异具有统计学意义(P<0.05);在治疗期间,两组患者均未出现明显的不良反应症状,差异无统计学意义(P>0.05)。结论:对腹泻患儿联合给药喜炎平与思密达很好的临床治疗效果、不良反应的发生率低,安全可靠,值得在儿科中推广应用。
Objective: To analyze the clinical effect and safety of combined treatment of Xiyanping and Smectite in children with diarrhea. Methods: A total of 116 children with diarrhea admitted to our hospital from January 2014 to December 2014 were randomly divided into observation group (58 cases) and control group (58 cases). The control group of children with Xiyanping treatment, the observation group in the control group on the basis of administration of Smecta. Analysis and comparison of two groups of children with the treatment effect and the incidence of adverse reactions. Results: The total effective rate was 55 (94.83%) in the control group and 45 (77.59%) in the observation group, the difference was statistically significant (P <0.05). During the treatment period, the two groups There was no obvious adverse reaction symptoms in patients, the difference was not statistically significant (P> 0.05). Conclusion: The combination of Xiyanping and Smectite in children with diarrhea has a good clinical therapeutic effect, the incidence of adverse reactions is low, safe and reliable, which is worth popularizing and applying in pediatrics.